Medicine Research.CRO
Latest round
- Series A
Last raised
- Mar 2025
Total raised
- Undisclosed
Investors
- 2
About Medicine Research.CRO
CRO operates as a Contract Research Organization providing essential services for pharmaceutical development. The company has engaged in two significant deals, with its most recent deal taking place on March 19, 2025. It has not publicly acknowledged any significant pivots in business strategy or operations, nor has it indicated any parent or subsidiary relationships., Ltd. specializes in a diverse range of services and solutions within the pharmaceutical and healthcare sectors. The company offers a comprehensive suite of Contract Research Organization (CRO) technical services, which include drug research, clinical trial support, and biobank testing services. These services aim to facilitate pharmaceutical development, enhance drug efficacy, and ensure compliance with regulatory standards, thereby addressing the needs of pharmaceutical companies and research institutions. Additionally, the firm provides registration consultation and Market Authorization Holder (MAH) services, which support clients in navigating the complex landscape of drug and medical device approvals in various international markets, including Europe and North America.Revenue generation for Beijing Huayao Kechuan is primarily driven by a B2B service model, where the company engages directly with pharmaceutical companies and research institutions. The firm’s transactional structure includes fixed-price contracts for specific research projects, subscription-based models for ongoing CRO services, and consulting fees for regulatory guidance. Each engagement typically involves detailed service agreements tailored to the specific needs of clients, ensuring a clear understanding of deliverables and timelines. The company’s flagship offerings, which include high-end formulation development and clinical trial management, are integral to its service portfolio, providing clients with a robust framework for advancing their pharmaceutical innovations. The company plans to introduce innovative solutions to enhance its CRO offerings by mid-2026. Furthermore, it aims to penetrate additional international markets, specifically targeting regions in Europe and North America, by the end of 2026. This strategic expansion is anticipated to augment its capacity to serve an increasing clientele in the pharmaceutical sector.
Who invested in Medicine Research.CRO
2 investors across 2 rounds
See all investors in Medicine Research.CRO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Medicine Research.CRO
Who invested in Medicine Research.CRO?
Medicine Research.CRO has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Medicine Research.CRO raised?
Medicine Research.CRO has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Medicine Research.CRO last raise money?
Medicine Research.CRO's most recent round on record is a Series A, in Mar 2025.
What does Medicine Research.CRO do?
CRO operates as a Contract Research Organization providing essential services for pharmaceutical development.
Where is Medicine Research.CRO headquartered?
Medicine Research.CRO is headquartered in Beijing, China.
Which VCs invest in companies like Medicine Research.CRO?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Medicine Research.CRO's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Medicine Research.CRO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.